HydraSolve® from Andrew Technologies is demonstrated equivalent to standard syringe control in new fat graft survival study in Aesthetic Surgery Journal
TUSTIN, Calif., Nov. 11, 2013 /PRNewswire/ -- Andrew Technologies, LLC announces the release of the first comparative fat graft survival study in which a liposuction device is demonstrated equivalent to standard syringe aspiration at 84 days post-grafting. Published in the November 2013 issue of Aesthetic Surgery Journal, this head to head study vs. traditional Coleman fat harvesting technique was led by Dr. Jeffrey Kenkel and Dr. Kathryn Davis of UT Southwestern. An abstract can be found at http://aes.sagepub.com/content/early/2013/11/06/1090820X13510526.abstract
According to Mark S. Andrew, MD, Founder and Chief Scientific Officer of Andrew Technologies, "I congratulate Drs. Kenkel and Davis on their well designed and well-executed study, which showed HydraSolve® lipoaspirate to be equivalent to the gold standard in fat grafting, the syringe aspiration method. The benefit of HydraSolve® is that it can quickly deliver a large volume of high quality fat for autologous fat transfer, which the syringe method can not do."
HydraSolve® is a novel liposuction device based on the same patented Tissue Liquefaction Technology™ that was launched in 2003 by Alcon as the AquaLase® Liquefaction Device, a modality on the Infiniti Vision System, for precision cataract surgery. Hydrasolve® combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve® cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while not liquefying or cutting blood vessels, nerves or connective tissue. HydraSolve® achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes. HydraSolve® is the first liposuction device FDA cleared for autologous fat transfer. For more information, please refer to www.hydrasolve.com
About Andrew Technologies, LLC
Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients' lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. Andrew Technologies is a venture capital funded company based in Orange County, CA and Haddonfield, NJ. Our primary investors are WFD Ventures http://www.wfdventures.com/ and NJTC Venture Fund http://www.njtcvc.com/.
SOURCE Andrew Technologies, LLC